Enter the last name, specialty or keyword for your search below.
The Alyssa Parian Lab works to identify early markers of dysplasia. We also study inflammatory bowel disease-associated cancers, conduct IBD clinical trials and examine IBD extraintestinal manifestations.
The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We’re working to identify the viral, host and immunologic factors that cause severe dengue illness.
Dr. Borahay's lab focuses on understanding pathobiology, developing novel treatments, and carrying out high quality clinical trials for common gynecologic problems with a special focus on uterine fibroids.
Dr. Braunstein's research focuses on inherited predisposition to hematologic diseases. His laboratory studies the inherited genetic changes in DNA that increase susceptibility to disease. Blood cancers such as myeloproliferative neoplasms and myelodysplastic syndromes are traditionally thought to be acquired disorders, however there is increasing evidence that inherited genetic changes play a role. In addition, Dr. Braunstein studies non-malignant blood diseases including atypical hemolytic uremic syndrome (aHUS) and related thrombotic disorders such as APLS, TTP and HELLP syndrome which are caused in part by genetic mutations. His work has identified a germline variants in the ERBB genes that predispose to hematologic malignancies. In addition, his research group found that patients with catastrophic APLS and HELLP syndrome frequently harbor germline mutations in complement regulatory genes. This has led directly to clinical trials designed to test the efficacy of complement inhibitio...n in patients with these disorders. Dr. Braunstein continues to work toward translating the scientific findings from the laboratory into improved care and treatment for patients. view more
Dr. Petty's laboratory interests focuses on antimicrobial chemotherapy, hospital-based medical practices, and internal medicine collaboration with ophthalmologic clinical trials.
Dr. Parikh's research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh's research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
His research is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, the development of clinical studies, and the design of clinical trials. Dr. Parikh's studies have refined the clinical definition in perioperative acute kidney injury and hep...atorenal syndrome, developed strategies to reduce kidney discard in deceased donor transplantation, and advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh's research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and improve the outcomes in patients with kidney disease.
Dr. Parikh has also been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology. view more
Dr. Ross and his research team have focused on Huntington's disease and Parkinson's disease, and now are using insights from these disorders to approach more complex diseases such as schizophrenia and bipolar disorder. They use biophysical and biochemical techniques, cell models, and transgenic mouse models to understand disease processes, and to provide targets for development of rational therapeutics. These then can provide a basis for developing small molecule interventions, which can be used both as probes to study biology, and if they have favorable drug-like properties, for potential therapeutic development. We have used two strategies for identifying lead compounds. The first is the traditional path of identification of specific molecular targets, such as enzymes like the LRRK2 kinase of Parkinson’s disease. Once structure is known, computational approaches or fragment based lead discovery, in collaboration, can be used. The second is to conduct phenotypic screens using ce...ll models, or in a collaboration, natural products in a yeast model. Once a lead compound is identified, we use cell models for initial tests of compounds, then generate analogs, and take compounds that look promising to preclinical therapeutic studies in animal models. The ultimate goal is to develop therapeutic strategies that can be brought to human clinical trials, and we have pioneered in developing biomarkers and genetic testing for developing strategies. view less
Dr. Clare Rock is an assistant Professor of Medicine, Division of Infectious Diseases at the Johns Hopkins University School of Medicine, Associate hospital Epidemiologist at the Johns Hopkins Hospital, and Faculty Member at Armstrong Institute for Patient Safety and Quality. Her research interest focuses the prevention of pathogen transmission in the hospital environment. This includes novel strategies of improving patient room cleaning and disinfection, including human factors engineering approaches, and conducting robust clinical trials to examine effectiveness of "no touch" novel technologies such as UV-C light. She has particular interest in carbapenem-resistant Enterobacteriaceae transmission in the hospital environment, including outbreak management, and transmission and epidemiology of Clostridium difficile. Her other area of interest is diagnostic stewardship, and the behavioral, cultural and human factors aspects of implementation of initiatives to enhance appropriate use of ...diagnostic tests. She leads a national initiative, as part of the High Value Practice Academic Alliance, examining strategies for appropriate testing for Clostridium difficile. This is a wider implementation of work that Dr. Rock conducted with The Johns Hopkins Health System facilities.
Dr. Rock has multiple sources of grant funding including from the Agency of Healthcare Research and Quality, Centers for Disease Control and Prevention, and industry. Dr. Rock is Vice Chair of the Society for Healthcare Epidemiology of America Research Network, and serves on the SHEA research committee. Dr. Rock earned her M.B.B.Ch. at the University College Dublin School of Medicine, National University of Ireland, and her MS masters of clinical science of research at the University of Maryland, where she received the MS scholar award for epidemiology. view more
Research in the Clifton O. Bingham III Lab focuses on defining clinical and biochemical disease phenotypes related to therapeutic responses in rheumatoid arthritis and osteoarthritis; developing rational clinical trial designs to test new treatments; improving patient-reported outcome measures; evaluating novel imaging modalities for arthritis; and examining the role of oral health in inflammatory arthritis.
The Dara Kraitchman Laboratory focuses on non-invasive imaging and minimally invasive treatment of cardiovascular disease. Our laboratory is actively involved in developing new methods to image myocardial function and perfusion using MRI. Current research interests are aimed at determining the optimal timing and method of the administration of mesenchymal stem cells to regenerate infarcted myocardium using non-invasive MR fluoroscopic delivery and imaging. MRI and radiolabeling techniques include novel MR and radiotracer stem cell labeling methods to determine the location, quantity and biodistribution of stem cells after delivery as well as to noninvasively determine the efficacy of these therapies in acute myocardial infarction and peripheral arterial disease.
Our other research focuses on the development of new animal models of human disease for noninvasive imaging studies and the development of promising new therapies in clinical trials for companion animals.
Areas of research in the David Shade Lab include data-management methods for clinical research, design and conduct of clinical trials, and internet usage for data acquisition and distribution.
The Douglas Ball Lab conducts clinical trials and pre-clinical laboratory studies of thyroid cancer. Our clinical trials, performed in collaboration with research staff in the upper aero-digestive group in the Sidney Kimmel Comprehensive Cancer Center, have included protocols for advanced radioiodine-refractory differentiated thyroid cancer and medullary thyroid cancer. Our pre-clinical research, conducted with Dr. Nelkin, Dr. Agrawal and other Kimmel Cancer Center researchers, includes pathogenesis and mechanisms of treatment resistance in medullary thyroid cancer, and pathogenesis and immune-directed therapy of anaplastic thyroid cancer.
Research in the Duvuru Geetha Lab focuses on renal diseases in patients with systemic vasculitis as well as BK virus nephropathy in patients who have undergone renal transplant. Our studies include clinical trials on the effectiveness of rituximab versus cyclosporine in treating idiopathic membranous nephropathy and a multinational study of belimumab with azathioprine for maintaining remission of granulomatosis with polyangiitis and microscopic polyangiitis. We also have conducted research on the treatment of ANCA vasculitis, particularly in kidney transplant patients.
The goal of the lab's research is to identify molecular abnormalities that can improve the outcome of patients with pancreatic cancer and those at risk of developing this disease. Much of our work is focused on translational research evaluating markers and marker technologies that can help screen patients with an increased risk of developing pancreatic cancer.
Thus, marker efforts have been focused mostly on identifying markers of advanced precancerous neoplasia (PanINs and IPMNs) that could improve our ability to effectively screen patients at risk of developing pancreatic cancer. We lead or participate in a number of clinical research protocols involved in the screening and early detection of pancreatic neoplasia including the CAPS clinical trials. We maintain a large repository of specimens from cases and controls with and without pancreatic disease and use this repository to investigate candidate markers of pancreatic cancer for their utility to predict pancreatic cancer risk.
...
In addition, we have been working to identify familial pancreatic cancer susceptibility genes and identified BRCA2 as a pancreatic cancer susceptibility gene in 1996. We participate in the PACGENE consortium and the familial pancreatic cancer sequencing initiative. My lab also investigates pancreatic cancer genetics, epigenetics, molecular pathology, tumor stromal interactions and functional analysis of candidate genes and miRNAs. Dr. Goggins is the principal investigator of a phase I/II clinical trial evaluating the Parp inhibitor, olaparib along with irinotecan and cisplatin for patients with pancreatic cancer. view more
Research in the Grant (Xuguang) Tao Lab explores environmental and occupational epidemiology topics, including workers' compensation and injuries, and nosocomial infections. We conduct research through clinical trials and systematic literature reviews, and also use cancer registry data and GIS applications in environmental epidemiological research. Our recent studies have explored topics such as the effectiveness of lumbar epidural steroid injections following lumbar surgery, the effect of physician-dispensed medication on workers' compensation claim outcomes and how the use of opioid and psychotropic medications for workers' compensation claims impacts lost work time.
The Johns Hopkins Head and Neck Cancer Tissue Bank enrolls patients and collects research specimens from Head and Neck Tumor patients, both cancerous and benign, with particular focus on Head and Neck Squamous Cell Cancer patients. It provides specimens to researchers both within the institution and outside.
Principal Investigator
Department
The Brain Health Program is a multidisciplinary team of faculty from the departments of neurology, psychiatry, epidemiology, and radiology lead by Leah Rubin and Jennifer Coughlin. In the hope of revealing new directions for therapies, the group studies molecular biomarkers identified from tissue and brain imaging that are associated with memory problems related to HIV infection, aging, dementia, mental illness and traumatic brain injury. The team seeks to advance policies and practices to optimize brain health in vulnerable populations while destigmatizing these brain disorders.
Current and future projects include research on: the roles of the stress response, glucocorticoids, and inflammation in conditions that affect memory and the related factors that make people protected or or vulnerable to memory decline; new mobile apps that use iPads to improve our detection of memory deficits; clinical trials looking at short-term effects of low dose hydrocortisone and randomized to 28 day...s of treatment; imaging brain injury and repair in NFL players to guide players and the game; and the role of inflammation in memory deterioration in healthy aging, patients with HIV, and other neurodegenerative conditions. view more
Principal Investigator
Leah Rubin, M.A., M.P.H., Ph.D.
Department
Neurology
Psychiatry and Behavioral Sciences
Radiology
HPTN (HIV Prevention Trials Network) Network Laboratory (NL) is responsible for collecting, testing and reporting results from biological samples; assisting in the development and quality assurance assessment of local laboratory capacity at the Clinical Trials Units (CTUs) participating in HPTN clinical trials (www.hptn.org); and identifying and implementing state-of-the-art assays and technologies to advance the scientific agenda of the Network.
Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesity and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans.
The Jean Kim Laboratory performs translational research in the
area of chronic rhinosinusitis, with a niche interest in the pathogenesis of hyperplastic nasal
polyposis. Studies encompass clinical research to basic wet laboratory research in
studying the underlying immune and autoimmune mediated mechanism of polyp growth and
perpetuation of disease. Human cell and tissue culture models are used. Techniques in the
laboratory include cell and tissue culture, real time PCR, immunoblot, ELISA, flow cytometry,
immunohistochemistry, electron microscopy, gene array analysis, and other molecular
approaches including genetic knockdowns. Approaches used in Dr. Kim’s clinical study
designs include prospective and retrospective analysis of patient outcomes and clinical
biomarkers, as wells controlled clinical trials.
While there has been an explosion of knowledge about human carcinogenesis over the last 2 decades, unfortunately, this has not translated into the development of effective therapies for either preventing or treating the common human cancers. The goal of the Isaacs’ lab is to change this situation by translating theory into therapy for solid malignancies, particularly Prostate cancer. Presently, a series of drugs discovered in the Isaacs’ lab are undergoing clinical trials in patients with metastatic cancer.
The ongoing drug discovery in the lab continues to focus upon developing agents to eliminate the cancer initiating stem cells within metastatic sites of cancer. To do this, a variety of bacterial and natural product toxins are being chemically modified to produce “prodrugs” whose cytotoxicity is selectively activated by proteases produced in high levels only by cancer cells or tumor associated blood vessel cells. In this way, these prodrugs can be given systemically to metastati...c patients without un-acceptable toxicity to the host while being selectively activated to potent killing molecules within metastatic sites of cancer.
Such a “Trojan Horse” approach is also being developed using allogeneic bone marrow derived Mesenchymal Stem cells which are genetically engineered to secrete “prodrugs” so that when they are infused into the patient, they selectively “home” to sites of cancers where the appropriate enzymatic activity is present to liberate the killing toxin sterilizing the cancer “neighborhood”. view more
The Kathryn Carson Lab investigates ways to improve medical research, particularly in the areas of brain and thyroid cancer, Alzheimer’s disease, atherosclerosis, hypertension, HIV and lupus. Our team seeks to help researchers optimize their studies through better study design, protocol and grant writing, data cleaning and analysis, and publication writing. We work with investigators from a wide range of departments through the Johns Hopkins Institute for Clinical and Translational Research.
Research in the Kawsar Rasmy Talaat Lab focuses on international health and parasitology, with an emphasis on vaccines, avian influenza and pandemic influenza. Our team conducts clinical trials of vaccines for a range of diverse pathogens, including flu strains that have the potential to reach pandemic status. Our studies seek to evaluate the safety and immunogenicity of vaccine candidates. We also have a longstanding interest in tropical medicine.
The Kayode Williams Lab conducts translational research on neuromodulation. We primarily examine the mechanisms and efficacy of spinal cord stimulation in treating neuropathic pain, peripheral neuropathies and peripheral vascular disease. Our clinical trials explore spinal cord stimulation in the treatment of painful diabetic neuropathy and the treatment of critical non-reconstructible critical leg ischemia. We also have a longstanding interest in the business of medicine and seek to enhance value propositions for hospitals and physician groups through more effective management of resources.
Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.
The Laura Hummers Lab participates in a number of clinical trials and clinical investigations at the Scleroderma Center at Johns Hopkins. We have a particular interest in the predictors of outcomes in scleroderma. We’ve established a prospective cohort of 300 scleroderma patients to identify incident vascular outcomes in the hopes of identifying new biomarkers for disease development and progression.
Research in the Lee Bone Lab uses community-based participatory approaches to promote health in underserved urban African-American populations. We conduct randomized clinical trials on cardiovascular disease, diabetes and cancer detection and control in order to test the success of community interventions. We focus in particular on making interventions sustainable and on implementing electronic education to improve communication.
Research in the Liudmila Cebotaru Lab studies cystic fibrosis transmembrane conductance regulator (CFTR) mutants. We also investigate corrector molecules that are currently in clinical trials to get a better understanding of their mechanism of action. A major focus of our research is on developing more efficient gene therapy vectors with the ultimate goal of developing a gene therapy for cystic fibrosis.
Clinical trials conducted in the Lonny Yarmus Lab focus primarily on minimally-invasive diagnostic testing for patients with lung cancer and local therapy options for malignant airway obstructions. We investigate ways to improve the early diagnosis of lung cancer, as well as the treatment of later-stage cancer, using the least invasive methods possible. We are also part of the LIBERATE clinical study for patients who have difficulty breathing and suffer from severe emphysema.
Work in the Marek Mirski lab explores the subcortical mechanisms of seizure propagation and cortical synchrony. The primary goal of our research is to develop methodologies for inhibiting seizures using site-specific subcortical electrical stimulation. Our identification of synaptically linked subcortical elements that contribute to seizure propagation has led to FDA-sanctioned phase III clinical trials to assess the use of targeted thalamic stimulation in patients with intractable seizures. We also conduct clinical research on the treatment of acute head injury, elevated intracranial pressure, cerebral edema, ischemic stroke and ICU sedation.
Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.
The Maureen Horton Lab conducts research on pulmonary fibrosis through the use of both preclinical models and human trials. Our studies have helped to develop novel, genetic, tissue-specific models of immune dysfunction, which have aided in defining the immune regulation of fibrosis and in the development of treatment strategies. We have used T-cell skewing immunotherapy to prevent and reverse chemical-induced lung fibrosis and have conducted clinical trials for idiopathic pulmonary fibrosis (IPF), which led to one of the first treatments that helped to improve quality of life in IPF patients.
Our Molecular Oncology lab seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Through comprehensive exome-wide sequence and genome-wide structural genomic analyses we have discovered that tumor cells evade immune surveillance by elimination of immunogenic mutations and associated neoantigens through chromosomal deletions. Additionally, we have developed non-invasive molecular platforms that incorporate ultra-sensitive measurements of circulating cell-free tumor DNA (ctDNA) to assess clonal dynamics during immunotherapy. These approaches have revealed distinct dynamic ctDNA and T cell repertoire patterns of clinical response and resistance that are superior to radiographic response assessments. Our work has provided the foundation for a molecular response-adaptive clinical trial, where therapeutic decisions are made not based on imaging but b...ased on molecular responses derived from liquid biopsies. Overall, our group focuses on studying the temporal and spatial order of the metastatic and immune cascade under the selective pressure of immune checkpoint blockade with the ultimate goal to translate this knowledge into “next-generation” clinical trials and change the way oncologists select patients for immunotherapy. view less
Dr. Rowan is actively involved in both outcomes and translational research relating to chronic rhinosinusitis and endoscopic skull base surgery. He has a keen interest patient-reported quality of life outcomes as well as those that pertain to smell and taste. Dr. Rowan is also involved in sinus-related clinical trials, pursuing new medical therapies and technological advancements for the treatment of patients with chronic rhinosinusitis.
Research in the Richard Chaisson Lab primarily examines tuberculosis and HIV infection, with specific focus on global epidemiology, clinical trials, diagnostics and public health interventions. Our recent research has involved evaluating a molecular diagnostic test for tuberculosis in HIV patients; observing TB responses during treatment of pulmonary tuberculosis; and examining antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa.
The Robert Wise Lab conducts clinical trials to study chronic obstructive lung diseases (COPD). We investigate inhaled corticosteroids in patients with mild to moderate COPD and the effectiveness of anti-inflammatories in allowing lung growth in mild to moderate asthmatic children. Our research includes exploring the efficacy of various treatments for asthmatic women who are pregnant and of lung-volume reduction surgery for emphysema patients. We also conduct studies of the clinical epidemiology, pathobiology and treatment of interstitial lung disease in patients with scleroderma.
The Roy Brower Lab conducts clinical trials related to the management of acute respiratory distress syndrome (ARDS). Our research also involves oxygen toxicity, a potentially fatal condition caused by too much supplemental oxygen.
The Saleh Alqahtani Lab has conducted clinical research on the management of fatty liver disease and viral hepatitis, including novel therapies. We’ve also been involved in various clinical trials related to liver cirrhosis, liver cancer and outcomes of liver transplant patients.
Research in the Sean Agbor-Enoh Lab explores topics within the field of pulmonary medicine. Our team also participates in clinical trials that explore new techniques for diagnosing rejection following an organ transplant. One current study is seeking to develop a new blood test that may be used instead of biopsies to diagnose rejection after transplant.
Research in the Sherita Golden Lab focuses on identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease. We conduct our research by incorporating measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications.
The Spinal Column Surgical Outcomes Laboratory aims to improve the neurological outcomes and functional capacity of patients undergoing spinal surgery. We collect large-scale retrospective patient databases and prospective patient registries to report high-quality data relating to the outcomes of neurosurgical operations. The laboratory participates in the National neurosurgical Quality and Outcomes Database (N2QOD). This multi-institutional collaboration has set forth a 3-year prospective study to benchmark quality and surgical outcome measures across several academic institutions. The Spinal Column Surgical Outcomes Laboratory specializes in biostatistical analysis of large-scale clinical databases, studying the outcomes of traditional and novel spinal procedures, quality control and cost-effectiveness research and clinical trials relating to spinal surgery outcomes.
Work in the Srinivasa Raja Lab seeks to better understand both the peripheral and central mechanisms that cause neuropathic pain, including various methods for treatment. A large focus of our research is on exploring the role of opioid and adrenergic receptor mechanisms in the management of chronic neuropathic pain. Our team also studies the mechanisms of spinal cord stimulation for treating chronic pain, and we have conducted controlled clinical trials in an effort to improve evidence-based practices for pharmacological treatment of neuropathic pain.
Research in the Steven Levin Lab focuses on chemical neurolysis, epiduroscopy (and training for physicians), opioid administration, and the use of alternative therapies for pain management. In collaboration with the American Society of Law, Medicine and Ethics and with funding from a Donahue Foundation Grant, we study social and ethical considerations in pain management. We have also been involved in clinical trials of novel analgesics.
Research in the Vestibular NeuroEngineering Lab (VNEL) focuses on restoring inner ear function through “bionic” electrical stimulation, inner ear gene therapy, and enhancing the central nervous system’s ability to learn ways to use sensory input from a damaged inner ear. VNEL research involves basic and applied neurophysiology, biomedical engineering, clinical investigation and population-based epidemiologic studies. We employ techniques including single-unit electrophysiologic recording; histologic examination; 3-D video-oculography and magnetic scleral search coil measurements of eye movements; microCT; micro MRI; and finite element analysis. Our research subjects include computer models, circuits, animals and humans. For more information about VNEL, click here.
VNEL is currently recruiting subjects for two first-in-human clinical trials:
1) The MVI Multichannel Vestibular Implant Trial involves implantation of a “bionic” inner ear stimulator intended to partially restore sensation... of head movement. Without that sensation, the brain’s image- and posture-stabilizing reflexes fail, so affected individuals suffer difficulty with blurry vision, unsteady walking, chronic dizziness, mental fogginess and a high risk of falling. Based on designs developed and tested successfully in animals over the past the past 15 years at VNEL, the system used in this trial is very similar to a cochlear implant (in fact, future versions could include cochlear electrodes for use in patients who also have hearing loss). Instead of a microphone and cochlear electrodes, it uses gyroscopes to sense head movement, and its electrodes are implanted in the vestibular labyrinth. For more information on the MVI trial, click here.
2) The CGF166 Inner Ear Gene Therapy Trial involves inner ear injection of a genetically engineered DNA sequence intended to restore hearing and balance sensation by creating new sensory cells (called “hair cells”). Performed at VNEL with the support of Novartis and through a collaboration with the University of Kansas and Columbia University, this is the world’s first trial of inner ear gene therapy in human subjects. Individuals with severe or profound hearing loss in both ears are invited to participate. For more information on the CGF166 trial, click here. view more
Principal Investigator
Charles Della Santina, M.D., Ph.D.
Department
Biomedical Engineering
Otolaryngology - Head and Neck Surgery
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
